PURPOSE: The aim of this study was to elucidate the clinical significance of preoperative Platelet-to-lymphocyte ratio (PLR) in @entity157 ( @entity157 ) @entity1 after thermal ablation. MATERIALS AND METHODS: We retrospectively reviewed 414 @entity1 with    @entity157 treated with ultrasound-guided thermal ablation percutaneously between January 2010 and March 2014. The correlation of @entity1349 ( @entity1349 ) with 15 clinical parameters was analysed by Cox multivariate proportional hazard model analysis. The best cut-off value of preoperative PLR was determined with time-dependent receiver operating characteristic (ROC) curve analysis. The value of PLR in predicting recurrence was analysed by Kaplan-Meier. RESULTS: Multivariate Cox proportional hazard model analysis showed that @entity5 differentiation, prothrombin time (PT), absolute lymphocyte count (ALC) and PLR were risk factors for recurrence in @entity157 @entity1 . PLR   >=    87.87 was considered for evaluation (AUROC   =   0.667; P   <   0.05), and 166 of 414 @entity1 (40.1%) had PLR of more than 87.87. During the follow-up period (12-52 months), the 1- and 3-year recurrence rates were 39.9% and 54.8% in the low PLR group, which were significantly better than those in the high PLR group (56.0% and 79.5%) (P   <   0.05). Kaplan-Meier analysis demonstrated that the @entity1349 in the low PLR group was 45.2% which was significantly higher than that of the high PLR group (20.5%) (X2   =   24.019, P   <   0.05). This result suggested that preoperative PLR is a predictor for recurrence followed thermal ablation in @entity157 @entity1 , and @entity1 with PLR   >=    87.87 indicated higher @entity1349 , which may improve the clinical management of @entity157 @entity1 . Further studies are warranted to validated this finding and test its clinical applicability in @entity157 .

Clinical significance of preoperative platelet-to-lymphocyte ratio in XXXX after thermal ablation: A retrospective analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity157 :: ('MESH:D006528', 'Disease') :: ['RHCC', 'recurrent hepatocellular carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['RFS', 'recurrence-free survival']
@entity157 :: (MESH:D006528,Disease) :: ['recurrent hepatocellular carcinoma']
